Greetings and welcome to Edwards Lifesciences fourth quarter 2025 results conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to your host, Gerianne Sarte. Thank you. You may begin. Thank you. Good afternoon and thank you for joining us. This is Gerianne Sarte. I am the incoming Senior Vice President of Investor Relations. With me on today's call is our CEO, Bernard Zovighian, and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Dan Lippis, our global leader of TAVR, and Daveen Chopra, who has global responsibility for TMTT, Surgical, and IHFM. Just after the close of regular trading, Edwards Lifesciences released fourth quarter and full year 2025 financial results. During today's call, management will discuss the results included in the press release and accompanying financial schedules, and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause these differences can be found in today's press release and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to constant currency sales growth, which is defined in the financial results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release. Quarterly and full-year growth rates refer to continuing operations. With that, I'll turn the call over to Bernard for his comments. Thank you, Gerianne, and welcome everyone. I am pleased to introduce Gerianne Sarte as our new head of Investor Relations at Edwards. Gerianne has an extensive background in MedTech and as a leader in our global finance organization prior to moving to this new position. You'll be seeing and hearing from her going forward, and I know she looks forward to getting to know you. Now let me turn to discussing Q4 and 2025 results. We delivered a strong quarter growing at 11.6% and a strong full year 2025 growing at 10.7%. This is the result of our differentiated strategy with a clear vision around three key elements, focusing solely on Structural Heart, solving large, urgent, and very complex patient needs, and pursuing unique opportunities to innovate and lead. This is only possible due to our deeply experienced teams, their excellent execution, and their commitment to patients worldwide. With our achievement in 2025, we are entering 2026 with strength and momentum globally, with many growth catalysts in each area across the company. Starting with TAVR, there is a renewed focus on SAPIEN across the healthcare ecosystem, led by the seven-year PARTNER 3 and the ten-year PARTNER 2 data, which confirm the long-term durability and proven valve performance of a SAPIEN platform. This data, presented last October at TCT, reinforced the confidence physicians and patients have in Edwards TAVR and set a new clinical benchmark for safety, efficacy, durability, and lifetime management of patients. In addition, the practice-changing EARLY TAVR trial is resonating with the clinical community, starting with the guideline changes in Europe. Together, all of these will have a lasting impact on the continued expansion of a SAPIEN platform globally. Continuing with TMTT, growth is fueled by a comprehensive portfolio of repair and replacement therapies and strengthened by new options for patients. These include the launch of SAPIEN M3, the scaling of EVOQUE, the upcoming introduction of next-gen PASCAL in Q4 of this year, and the introduction of PASCAL for U.S. tricuspid patients also in Q4. Together, these are significant advancements for mitral and tricuspid patients and represent large opportunities to achieve our $2 billion revenue expectation for TMTT in 2030. Overall, for Edwards in 2026, we have increased confidence in meeting our 8%-10% sales growth guidance as well as in our EPS guidance. We are looking forward to an updated national coverage determination for TAVR, which may present a potential tailwind later this year, recognizing that our impressive results in 2025 have set a higher bar for 2026, especially in the second half. Long term, we are well positioned to execute our compelling growth strategy, and specifically over the next three years, we will be pioneering new therapies, launching next generation of existing technologies, as well as expanding indication to impact more patients. Our talented team of 16,000 employees create, develop, and enable treatment of patients globally with a highly differentiated and complete portfolio of therapies to address aortic, pulmonic, mitral, and tricuspid valve diseases. We take very seriously the responsibility of investing in the development of safe and effective valve therapies with proven long-term durability. Valve technology requires dedicated focus and generation of world-class clinical evidence that will continue to differentiate Edwards. I am confident that our technology will remain the first choice of clinicians to transform the care of their patients. Leveraging our experience, we are extending into structural heart failure and aortic regurgitation, or AR, for the many patients who are not well served today. This will create additional growth opportunities and extend our structural heart leadership. In 2027 and beyond, we continue to expect average annual sales growth of 10% with constant currency operating margin expansion as we continue to address patients in need by advancing novel therapies to extend lives, improve quality of life, and provide greater impact and efficiency for health systems. Now, I will provide an overview of Q4 sales performance by product group. TAVR overall procedural growth in the quarter remained in the high single digit, and for Edwards, TAVR fourth quarter global sales of $1.16 billion increased 10.6% over the prior year and slightly sequentially over a high Q3, which was inconsistent with typical summer seasonality. The Q4 performance reflected clinicians' elevated focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis. Edwards TAVR procedural growth was comparable across the U.S. and OUS, and our average price and competitive position were stable on a global basis. While EARLY TAVR studied TAVR AS patients without symptoms, we are encouraged by the impact this study has had on increasing the sense of urgency for the treatment of patients who have symptoms. The timely referral, evaluation, and treatment of patients with severe aortic stenosis is fueled by a large and growing body of evidence on the long-term outcomes of SAPIEN valves. Our position as the only TAVR therapy with an asymptomatic indication will provide additional benefits, along with the potential of an updated TAVR NCD and U.S. and Japan guideline evolution. These additive catalysts provide multiple layers of durable growth. In addition to the long-term data presented at TCT, more than 30 distinguished physician thought leaders published the first-ever AS global consensus document. This validates the movement away from the outdated practice of watchful waiting and further supports the importance of guideline-based management of severe AS patients. Let me turn to some U.S. commentary. We saw intentional and urgent treatment of severe aortic stenosis patients fueled by a large and growing body of world-class evidence on the SAPIEN platform and the increased adoption of SAPIEN 3 Ultra RESILIA. We are pleased that CMS formally opened the process to reconsider the NCD for TAVR. This decision has the potential to improve timely and equitable access to life-saving TAVR therapy. The initial 30-day public comment period closed on January 14, and we look forward to the process continuing. In Q4, we expanded our partnership with the American Heart Association as the founding sponsor of a heart valve initiative. This new initiative is focused on timely diagnosis and treatment to save lives and improve care for millions living with heart valve disease. It is a multi-year program to elevate heart valve disease as a critical focus area for hospital systems through adherence to specific quality metric-based care, expanded data collection, and hence healthcare professional education and patient engagement. In Europe, fourth quarter results reflected healthy underlying TAVR procedure growth as well as our consistent execution across the region. Updated guidelines from the European Society of Cardiology and the European Association for Cardiothoracic Surgery are reshaping clinical discussions around proactive disease management and reinforcing the role of TAVR for a broader patient population. We also continue to see modest year-over-year share improvement in several key countries, strengthening our leadership position in the wake of a competitor's exit. In summary for TAVR, we are pleased with our strong Q4 result and full year 2025 performance. SAPIEN growth globally was supported by rising clinical urgency for intentional proactive disease management and long-term evidence demonstrating the proven durability and valve performance of SAPIEN 3. As we look ahead, we are well positioned to continue the momentum and remain focused on driving our patient access strategy, generating additional clinical evidence, and delivering on our innovation pipeline to address the growing patient needs across the world. This strength reinforces our confidence in Edwards TAVR as a durable growth engine and a meaningful contributor to long-term value creation. Now let's turn to our TMTT product group. Our comprehensive portfolio of repair and replacement therapies offers meaningful opportunities to physicians to best treat their mitral and tricuspid patients. This drove another strong quarter, with TMTT growing over 40% to $156 million. We were also pleased that for the full year, TMTT sales exceeded $1 billion. Continued global adoption of PASCAL and EVOQUE contributed to overall growth. Physicians continue to provide positive feedback on PASCAL's differentiated benefits for treatment of their patients who need transcatheter edge-to-edge repair. With EVOQUE, we are expanding the number of centers and training more physicians while focusing on excellent patient outcomes. The recent FDA approval of SAPIEN M3 expands our mitral portfolio in the U.S. and represents the first transcatheter replacement option for suffering from mitral disease. Similar to our other therapy launches, the strategic introduction of SAPIEN M3 is leveraging our proven high-value support model and focusing on outstanding clinical outcomes. We are initially opening sites that were previously in our ENCIRCLE pivotal clinical trial, and physician interest in this technology is growing. With PASCAL and EVOQUE growing globally and now with the introduction of SAPIEN M3 in the U.S. and Europe, Edwards continues to deliver on our vision of offering a portfolio of therapies to treat more mitral and tricuspid patients. Overall, PASCAL adoption globally is delivering differentiated outcomes for patients. The introduction of next-gen PASCAL in Q4 will further distinguish this important therapy for patients who need edge-to-edge repair. The upcoming U.S. approval of PASCAL for tricuspid patients will provide an enhanced therapy alternative, and the scaling of EVOQUE and launch of SAPIEN M3 will further advance treatment for tricuspid and mitral patients. This represents multi-layer growth opportunities starting in 2026 and contributing to achieving $2 billion revenue in 2030 and additional growth beyond. Finally, this year, we continue to expect sales in the range of $740 million-$780 million. In our surgical product group, fourth quarter global sales of $254 million increased 2% over the prior year. The underlying fundamentals of our surgical product group remain strong, while growth in Q4 was impacted by end-of-year distributor inventory adjustments in one country. Full year surgical sales grew 4.3% and for the first time exceeded $1 billion. We continue to expect mid-single digit sales growth rate in Surgical in 2026, driven by continued adoption of our RESILIA therapies that offer extended durability of our surgical therapies, including INSPIRIS, KONECT, and MITRIS. We were encouraged by new data presented at the recent STS meeting, including strong one-year data from the MOMENTIS study. MOMENTIS is studying long-term durability for the Edwards MITRIS systems for surgical mitral valve replacement, and one-year results from the study demonstrated 100% freedom from SVD, impressive stable hemodynamic performance, and excellent safety. This specifically designed surgical valve is customized for mitral patients with advanced and improved care. We are also pursuing multiple new innovations to advance surgical solutions for patients, including left atrial appendage closure, or LAAC. This is a new therapeutic area that is a complementary solution to specific valvular procedures, and we are planning on a preliminary introduction of our new surgical LAAC technology later this year. In summary, we still expect to deliver our mid-single digit sales growth rate guidance in 2026. Finally, we are looking forward to seeing 10-year data from our COMMENCE trial at the AATS conference in May, studying long-term durability of our best-in-class RESILIA tissue. Now, Scott will cover the details of the company's financial performance. Thanks, Bernard. Today, I will provide a wrap-up of 2025, including detailed results of our fourth quarter and guidance for the first quarter and full year 2026. We were pleased with our better-than-expected Q4 sales performance, with strength across all product groups. Total sales of $1.57 billion grew 11.6% year-over-year. Our adjusted earnings per share was $0.58. This lower-than-expected EPS was driven by higher spending on patient access initiatives and a higher-than-expected tax rate. It is important to note that we have increased confidence in our 2026 earnings per share guidance of $2.90-$3.05. Our GAAP EPS for the quarter was $0.11, which included one-time charges related to the JenaValve acquisition that did not close, as well as litigation expenses. A full reconciliation between our GAAP and adjusted EPS for this and other items is included with today's release. And now I'll cover additional details of our P&L. For the fourth quarter, our adjusted gross profit margin was 78.3%, in line with our expectations, compared to 79.0% in the same period last year. This expected year-over-year change was driven by additional manufacturing expenses related to the fast expansion of new therapies. We continue to expect our full year 2026 adjusted gross profit margin to be within our original guidance range of 78%-79%. Selling general and administrative expense in the quarter was $603 million, or 38% of sales, compared to 35% of sales in the prior year. We increased SG&A spending in the fourth quarter to fund strategic investments in order to amplify patient access to therapy, such as EARLY TAVR education, investment in field resources, and the AHA Heart Valve Initiative. Some of this strategic spending was delayed from previous quarters in the year. Research and development expense was $268 million in the fourth quarter, or 17.1% of sales, compared to $271 million, or 19.6% of sales in the same period last year. This decrease in R&D as a percentage of sales reflects our strategic prioritization of investments in our expanding structural heart portfolio. We continue to expect 2026 R&D as a percentage of sales to be approximately 17%. Fourth quarter adjusted operating profit margin of 23.7% was aligned with our previous guidance of mid-20%. Our full year 2025 adjusted operating profit margin of 27% was within our original expectations for the year. For 2026, we expect approximately 150 basis points constant currency operating margin expansion, which includes less spending related to removing JenaValve from our operating plans for the year. We continue to plan for 50 to 100 basis points of operating margin expansion annually, on average, in 2027 and beyond. We continue to plan to deliver leveraged earnings per share. Turning to taxes, our reported tax rate this quarter was 29%, or 17.9% excluding the impact of special items, which was above our expectation for the quarter driven by Pillar Two impact and country income mix. We continue to expect our 2026 tax rate, excluding special items, to be between 16% and 19%. Turning to the balance sheet, we continue to maintain a strong and flexible balance sheet with approximately $3 billion in cash and cash equivalents as of December 31st. Edwards currently has approximately $2 billion remaining under its share repurchase authorization. Average diluted shares outstanding during the quarter were 582 million. We continue to expect average diluted shares outstanding for 2026 to be between 580 million to 585 million. Foreign exchange rates increased fourth quarter reported sales growth by 170 basis points, or $20 million, compared to the prior year. FX rates had minimal impact on our fourth quarter gross profit margin compared to the prior year. Relative to our October guidance, FX rates had a nominal impact on fourth quarter earnings per share. At current rates, we now expect FX to have an approximately $40 million upside to full year 2026 sales compared to the prior year. I'll finish with comments related to our outlook. We have increased confidence in meeting our 2026 full year sales growth rate guidance of 8%-10% and earnings per share guidance of $2.90-$3.05. The product group sales guidance we provided at investor conference remains unchanged. For the first quarter, we're projecting sales of $1.55 billion-$1.63 billion. We expect slightly higher growth rates in the first half of 2026, following unusual summer seasonality that benefited 2025. We are expecting adjusted EPS in Q1 of $0.70-$0.76, representing mid-teens growth at the midpoint of that range. With that, I'll pass it back to Bernard. Thank you, Scott. In closing, we finished 2025 strong and achieved many lasting catalysts. We have increased confidence in our top-line and bottom-line guidance for 2026. Our strategy of focusing on Structural Heart is demonstrating impactful results for the company and the patients we serve, and is positioning us for long-term sustainable growth and value creation. With that, I will turn it back over to Gerianne. Thank you, Bernard. We're ready to take your questions. As a reminder, please limit the number of questions to one plus one follow-up to allow for broad participation. If you have additional questions, please reenter the queue and management will answer as many participants as possible during the remainder of the call. Thank you. To ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question comes from Robbie Marcus with JPMorgan. Please state your question. Oh, great. Congrats on a good quarter. Thanks for taking the questions. Two for me. First, maybe just on TAVR, 10.6%, another very strong quarter. I would have to imagine you're taking some share, even excluding the Boston Scientific exit. So maybe just speak to the strength you're seeing, the confidence in it, and any regional differences. And just one thing, if you can talk to volumes versus sales, I imagine the delta is price, but I had some questions on that. Thanks. Robbie, good afternoon, everyone. Yes, one is we are very pleased about the quarter overall and the year for Edwards. With regards to TAVR, very pleased about the quarter, like you said, growing 10.6% year-over-year. What we see is truly the result of our strategy here, where last year we brought very compelling evidence: EARLY TAVR, PARTNER 3 seven-year, PARTNER 2 10-year. All of this gave confidence. All of this also enabled a renewed focus on TAVR as a category and specifically the SAPIEN platform. So this is creating physicians to talk more about TAVR, to talk more about SAPIEN. This is enabling a physician to treat their patient a little bit early. This is also enabling providers to prioritize TAVR. So it is all of that together. But I'm going to ask Dan to give you more specific details about the quarter. Yeah, thanks, Bernard. And Robbie, you're spot on, right? The overall procedural growth rate in the quarter was in the high single digit, and so there is a gap. You're absolutely on the money as far as share gain and pricing contributing to that gap. Largely on the share perspective, I mean, the share gain that we had from the Boston Scientific exit contributed a big chunk of that. We're pleased to see the stickiness of that share gain from quarter three to quarter four. We took our piece of that, but most of the competitors in Europe also benefited from Boston's exit. I would say that we benefited about in line with our competitive position in the market. But if you look at globally, overall, our competitive position remains relatively stable, I would say. I mean, for sure, we're not weaker in Q4 than we were in Q3. But another piece of this is S3 UR penetration, right? And we continue to see very strong adoption of this outstanding platform, a lot of positive feedback from physicians. And so this is also contributing, like you mentioned, a little bit on the price side. Great. Maybe, Scott, just if you could talk to the increased spend on market access you highlighted. In fourth quarter, step-up in SG&A was roughly $100 million, which is pretty substantial. So maybe just dig into that. Where'd the spending go, and how should we think about that rolling in? Do we think of that as a one-time cost? Thanks. Yeah, thanks, Robbie. Appreciate the question. We had planned a step-up in the fourth quarter spending, and we decided to be aggressive in light of the reception we were getting to the things Bernard mentioned earlier, the asymptomatic trial, the seven-year results, the 10-year results. We intentionally upped the spending in the fourth quarter, $112 million year-over-year. We were still in operating margin terms in the area that we had expected for the fourth quarter. We had said mid-20%, and that was sort of in the range of where we came in. We invested more aggressively in patient access, so asymptomatic amplification. Bernard mentioned the American Heart Association partnership. We've also been reinforcing our field force in THV and also in TMTT. Some of this spending was delayed from earlier quarters in 2025. Following this elevated level of spending in Q4, we are planning a more moderated operating expense growth and SG&A expense growth in 2026, which is how we get to the operating margin guidance of the high end of our original 28%-29%. The other benefit in that margin increase or margin expansion is the exclusion of the original spending that we had planned for JenaValve. Maybe, Dan, you want to talk a little bit more about some of these initiatives? Yeah. I think a couple of big ones here, right? So with the change in the European guidelines, this is the biggest shift that we've seen in over 10 years. And it's a real important shift from watchful waiting to intentional and urgent treatment of severe aortic stenosis earlier in the disease pathway. This is a big shift. It involves change management and change of behavior, particularly at the referral level. And so we see an opportunity here to bend the curve of adoption of these guideline changes. And so we have a number of significant amplification programs that we have started to implement in Europe. This is a big one. Second one, as Scott and Bernard mentioned, our partnership with the AHA. This is an important one, and this is a multi-year partnership. It's designed to do the same thing, democratize and educate on the importance of treating earlier in the disease pathway for aortic stenosis. This is all designed to improve diagnosis and treatment of severe AS through guideline-based care, through extended data collection, but also heavy on education. These are two big ones. We also invested further in some of the sort of short-range pilot stage marketing programs to improve treatment rates and patient and referrer education in the United States. Like Scott said, there are some field-related we're very much a high-touch field clinical field force. With volumes increasing, we need to get ahead of those resources in the field. They take time. They take time to train and get people certified. So we got ahead a little bit of that, but also a big chunk we got behind early in the year, and a lot of that caught up with us in Q4. So they're the big items. Thank you. And your next question comes from Travis Steed with Bank of America. Please go ahead. Hey, everybody. Congrats. Just wanted to maybe focus on for TAVR and total company growth, anything to kind of call it for cadence over the year. And wasn't clear on an organic basis what Q1 was to me since I didn't have the FX impact in Q1. And any comments on kind of the January trends that you've seen so far to give you confidence in the guide and how to follow up? Yeah, thanks, Travis. Yeah, so I mentioned that we expect about $40 million of tailwind from FX to sales. And this has changed since our investor conference. A lot of that falls in the first quarter. And so we're expecting Q1 sales growth on a reported basis to be about 300 basis points higher than the underlying growth that we are expecting in Q1. Now, remember, the first-half growth rates in 2026 should be higher than the second-half growth rates. And maybe Dan will ask you to talk a little bit more about that. Yeah, thanks, Scott, and hi, Travis. Yeah, it's true. The growth rate in our guidance moves down a little bit over the course of this year, as previously we guided that the front half will be stronger than the back half in 2026. And this is because we have much tougher, much higher year-over-year comps in the second half. We also applied classical seasonality and other assumptions to the year that weren't the case in 2025. That makes it a little bit more of a challenge. But the Q4 results that we had in 2025 give us increased confidence in our six to eight guidance. And this is really important. On top of that, we have these meaningful tailwinds and catalysts later in the year. That give us confidence in the mid-to-high single-digit beyond 2026. Got it. And another follow-up on the TAVR NCD. You called it a potential tailwind later this year. Just wanted to kind of think about how you're seeing that help growth more centers, faster patient pathways. And if you read the public comments, they're all mostly positive on expanding the indication, but there's a bit more debate on the care team. So curious if you think how that shapes up in the final and how it might impact the different scenarios you're thinking about. Yeah, so I'll take this one. I think, obviously, it's very, very important. The first phase first of all, it's important that the process was formally reopened. That was really important. That happened right before the end of the year. The first phase is now over, as Bernard mentioned. So we expect the initial draft around the June timeframe. There'll be a second round of public commentary at that point. And then assuming that the normal CMS process follows, the final determination could be in the Q4 timeframe. So if you think about impact for 2026, negligible, but probably important and more relevant in 2027 and beyond. Now, the key priority areas for us is to ensure timely and equitable access to care for patients, right? The big win for patients would be coverage to label and any changes that may reduce procedural complexity or help improve equitable access to care. So that's what we're focused on. But we need to see what the draft looks like, and we look forward to the process continuing. And like you mentioned, we're also pleased that most of the commentary was positive and largely in line with our thinking. Thank you. Your next question comes from Larry Biegelsen with Wells Fargo. Please state your question. Good afternoon. Thanks for taking the question. Two from me. I wanted to just ask about the LAA opportunity. How big is that market today? There's a competitor that has a device with sales of, I think, over $200 million. How is yours differentiated, and how do you want us to think about your LAA sales ramp over the next few years? I had a follow-up. Yeah, thanks, Larry. We apply always the same filter. When we decide to get into a new space, it is all about, is there a big unmet patient needs? Can we have an impact? Can we bring differentiated technologies? And so we look at this one, and we say yes, yes, and yes. So how big it is, we don't know very well this segment yet. But we believe there is some technology out there. We believe there is still unmet patient needs. And long term, we believe we can have an impact here. But I'm going to ask Daveen, which is very close to this one, to add some comments. Yeah, thanks, Bernard. Thanks, Larry, for the question. Yeah, obviously, as we mentioned, we're looking to enter the market later this year. If you look at existing technologies out there, we think there's still unmet patient needs. That's where we believe, obviously, that we can come out with a technology in this new therapeutic area for Edwards Surgical. We can come out with a solution that can really help patient care. We see this as a complementary solution to our specific valvular procedures that we're already in. As a result of that, we kind of see kind of a measured commercial rollout, an opportunity to be a growth driver in the future for Edwards Surgical. That's super helpful. Bernard, we saw the long list of catalysts in 2026 in your press release today. I think people will notice that you didn't mention moderate AS. Can you talk about why you left that out and how you're thinking about the moderate opportunity today? Thanks for taking the questions. Thanks, Larry. I'm glad you saw a long list. Indeed, it is a very long list. Let me first talk a little bit about why all of these catalysts, and then we get to your question about moderate. The list is very long because of our very unique strategy where we invest early. We are very committed. We have a flawless execution. I'm sure you have seen that. The kind of result we have had in 2025 is pretty spectacular, financially, having all of these catalysts, new technologies, new evidence, lasting evidence, lasting impact. All of them are basically in play for this year. With moderate, for sure, moderate is a big category. We know that the moderate prevalence is bigger than the severe one. We know it is big, but at the same time, we don't know what the study result will be. So we are waiting to know more about PROGRESS, the PROGRESS trial, which will be presented at TCT to talk more about it. At least what you have seen is where we know for sure when it is coming and the type of impact we are going to have. PROGRESS and moderate, big opportunity. We don't know yet the study results. Thank you. Your next question comes from David Roman with Goldman Sachs. Please state your question. Thank you. Good afternoon, everybody. I was hoping to go into a little bit more detail on the comments regarding lifetime management for TAVR and maybe more specifically talk about what you think the implications will be to valve and vendor selection and balloon expandable versus self-expandable and how that might end up being a contributor to incremental market share gains as you think about the TAVR business here in 2026 and beyond. So I know that Dan has a lot of passion about this one. So I'm going to let Dan talk about this. No, you're on the right point, David. I mean, look, the evidence and when I say evidence, I'm talking the EARLY TAVR evidence, the sub-analyses from EARLY TAVR, the evidence that the likes of Philippe Genereux has published now on acute valve syndrome. And then you've got PARTNER 3 and PARTNER 2 long-term data on top of this all pointing to the fact that you're going to get a better clinical and economic benefit if you treat earlier in the disease pathway. This is a huge shift. And it changes the conversation between doctor and patient. So if you can imagine a year ago or a little bit more, it might have been something along the lines of, "Let's see if we can eke this out another six months or 12 months," or maybe a patient would want to thinking that they're trying to time their treatment and trying to figure out how to make their valve last as long as possible to avoid secondary or tertiary procedures. And this conversation has completely shifted because the evidence says that the benefit of doing that is not there's no upside to that, right? There's no upside to waiting anymore. And so this brings into the very important conversation and the concept of Lifetime Management. This is very, very important because you got to get the first procedure right to make sure you've got options and the right options for patients for their second procedure, whether that be another valve-in-valve or whether that be coronary artery access, PCI, or what have you. And so we think our platform is uniquely positioned both acutely and with Lifetime Management options, whether that be secondary or tertiary procedures. And I think that's going to be one of the key value propositions that we have not only immediately but in the years to come. And maybe just a clarification there. So in that scenario, is it reasonable to expect that just a significant percentage of patients receiving TAVR, either in the asymptomatic or call it the sub-75 population, that creates a unique opportunity for SAPIEN? And maybe just my follow-up, I'd ask here on capital allocation. You've obviously pulled the JenaValve deal did not end up coming to fruition. You bought back a good amount of stock last year, but you've also made some key hires to the business development team. Maybe just talk to us about your latest thinking here on capital allocation. Yeah, so as far as the look, whether it be younger patients or whether it be elderly patients, there's a good chance now with modern medicine and the way that this is going that patients will outlive their first valve. I mean, I think lifetime management considerations is not just now for youthful patients. In fact, more and more, we find ourselves in scenarios where certain valve platforms were chosen with the idea that the patient would not outlive that valve and then finding the options for that patient limited at that time point, which is really disappointing. This Lifetime Management thing, getting the first procedure right upfront, is a big thing. It is a conversation that everybody is focused on in the clinical community. Now, as far as strategic allocation, look, we think valve-in-valve and whether you throw in leaflet modification or other types of things associated with secondary procedures, we think this is going to be very real. It's small now, but it will be growing. It's all about the denominator, right, and numerator. So we're looking at ways, as we always do, to lead in this space. That's something that we're looking at very, very closely. The other thing that, obviously, we do is we look at how we apply our field force here and how we invest in our field force and what kind of value that we bring with our service model as these conversations and these types of procedures evolve in terms of how to get the best outcome for a patient at any given time. On capital allocation, David, our priorities have not changed. Our first priority is investing in the business to support our growth. That comes in the form of making sure we've got sufficient production capacity. As we mentioned at the investor conference, we're increasing our production capacity to keep up with the growth in TAVR and TMTT and Surgical. It also involves making external investments. So we've got a number of different activities underway. We've always been active in M&A. As you know, most of the things that we invest in or purchase tend to be smaller in size because we're focused on Structural Heart. But that's going to be a continual direction for allocation of capital. And then share repurchase is one of our best ways to return capital to shareholders. And we continued our share repurchase activities in the fourth quarter. We bought back about $40 million, bringing the total repurchase in 2025 to just under $900 million. We still have about $2 billion of authorization remaining. And you should expect that we're going to continue to look for opportunistic times to repurchase more shares. Thank you. And your next question comes from Joanne Wuensch with Citibank. Please state your question. Good afternoon, and thank you so much for taking my question. Could you give us a little bit of a state of the union on how M3 is being taken up in the United States and what impacts are going outside the United States? And then if you could just sort of flesh out and give a little bit more color on the guideline changes that are happening in Europe and how to think about those impacts for the remainder of the year. Thank you. Hey, thanks, Joanne. Its Daveen, I appreciate the question. Talking a little bit about the SAPIEN M3 launch, we're just starting in the U.S., right? We got approval, obviously, right before the end of the year. And it's kind of scaling in line with our expectations here in the U.S. of we're just starting to open up centers. Really focusing on centers who are in our ENCIRCLE pivotal clinical study first. In Europe, we're scaling in line with expectations as well, but it's still pretty early in the process. I think what we like that we're seeing is that we're getting really high procedural success, and we're getting really great patient outcomes. I remember I was with a patient just the other week who had previously had mitral valve surgery and then needed an M3 because his surgery had failed. And for him, hearing about the difference his life made when he had no other TEER or surgical alternatives with mitral regurgitation really hurting his life and how he just got so much better, it warmed my heart so much to kind of hear that. So because of that, we're seeing this physician excitement because there's a group of patients who don't really have TEER or have great surgical options for which M3 really becomes a good opportunity. So for us, we're continuing to appropriately kind of scale up, open up new centers, and bring this therapy to new patients. So that's kind of SAPIEN M3. And maybe moving on to kind of European guidelines, do you want to start with TAVR guidelines? Or the European guidelines, or I can talk about the FMR guidelines a little bit. So yeah, so on the European guidelines with FMR, they're now class one for functional mitral regurgitation for reduction of heart failure hospitalizations. So we're seeing, I think, increased awareness specifically in mitral and tricuspid, increased awareness for these two diseases and increased kind of referrals happening with these guideline shifts. So we see it as helping continue that double-digit TAVR market growth that we've been seeing. And maybe passing on to TAVR for a comment on the guidelines, Dan? Yeah, Joanne, as you may recall, the guidelines on the TAVR side changed in a meaningful way on two fronts. One is they reduced the age recommendation for TAVR going from 75 to 70, right? That's one big element of the change. And then the other element was this whole concept of recommending proactive disease management regardless of symptom or heart function. So this is basically changing the dogma of watchful waiting in Europe. And so this is a huge shift. Now, that requires a lot of education, you can imagine. We're seeing definitely, we did see healthy procedural growth in Q4 in Europe, and some of the large countries contributed that in a meaningful way. But the way that we look at this is the guidelines won't be a light switch, whether it be in Europe or the U.S. or Japan, but give us an opportunity as those get disseminated, as those get democratized, and then put into practice. It's just layers and layers of durable growth for us. And so that's kind of how it's playing out. Not a light switch, but definitely momentum. Thank you. Your next question comes from Matt Taylor with Jefferies. Please state your question. Hi, thanks for taking the question. I wanted to dig into the better performance we've seen in TAVR, especially in the U.S. the last couple of quarters, and just ask you what you thought was causing that. You're not benefiting from Boston. Are you really gaining share? Can you estimate how much EARLY TAVR has been contributing? Or are there other factors? What's really caused the increase in growth in the U.S. in the last couple of quarters? So yeah, thanks for the question. And I think without trying to be on repeat here, but this data, this very, very compelling data, not just on the EARLY TAVR and the asymptomatic side and not just clinical, but also economic data. I mean, I can't stress how important the economic data, benefit of the economics, treatment of patients, and the hospital economics earlier in the disease pathway is having an effect as much as the clinical data. So these two things tied with definitive durability data is creating a wave of confidence in the community to have a different conversation. It is also forcing, if you like, the aortic stenosis patient, the TAVR patient, to be prioritized differently and to be treated with urgency, right? Typically, you might see a little bit more rearranging of the patient list to bring more sick patients to the front of the list and the more healthier patients towards the back of the list rather than just getting through the list. And this conversation is completely different now, and people are focusing on this intentional and urgent treatment of symptomatic AS. So this is regardless of whether the patient is asymptomatic or not. This is the impact that it is having on symptomatic aortic stenosis is what we see largely driving our growth. When we look at the claims data, we don't see asymptomatic patients coming in in waves through the claims data. And that shouldn't be a surprise because the NCD doesn't cover asymptomatic indications at the moment. So right now, that's not a huge surprise. What we do see, though, since the indication in the United States, we do see increase in the number of echos. We do see increase in the number of referrals. We do see a decrease in time from referral to CT, which is the heart team evaluation. And interestingly enough, we do see a relatively sharp increase in stress tests for patients. And nobody typically likes to do stress tests. And so that's also an interesting finding that we see in the data. And so definitively, this is all positive momentum, and it's driving a lot of growth. But as I mentioned before, the other thing that is supporting and contributing to the performance in Q3 and Q4 is the success of SAPIEN 3 Ultra RESILIA. That's making a meaningful contribution to our performance, and we're pretty happy with that. Big picture here, if you process all of this that Dan talked about, this is what gives us confidence in our guidance for the year for TAVR, 2026 to 2028 and our guidance beyond 2026 for TAVR from mid- to high-single-digit. All what we are doing right now, all the things we have been doing, all of these catalysts are impacting severe symptomatic patients. And so the asymptomatic patients are still in front of us, and this is why we are so confident as to have TAVR as a durable growth opportunity for Edwards. Thank you. Thank you. Thank you. Y our next question comes from Vijay Kumar with Evercore ISI. Please state your question. Hey, guys. Thanks for taking my question. My first one was a quick housekeeping ask. I think you called it that TAVR was impacted by some distributor adjustments. Could you quantify what that is? And is the Q1 guidance implying a 10% TAVR growth? Sorry, Vijay, could you say the first part of your question one more time, please? Sorry. On TAVR, you called out a distributor impact in Q4. Could you quantify what the impact is? Are those sales coming back in Q1? And I'm just curious on what gets us to Q1 sales guidance. Is it TAVR or remodeling TAVR to 10% growth? Yeah, sure. Thanks for the question. Yeah, the surgical inventory adjustment was in one country. It was at the end of the year, and it was really adjusting inventories in the distribution channel. In China, we go through distributors, and we work very carefully on managing inventory levels. And so this is just something that we did at the end of the year. We still expect mid-single-digit growth from surgical in 2026 and beyond. So think of this as a one-time event. Sorry, Q1? Yeah, so Q1, the guidance implies, I mentioned before, on a reported basis, about 300 basis points higher than the underlying growth guidance. We haven't broken out specific underlying growth guidance, but know that the growth in the first half of the year is higher than the growth in the second half of the year. And overall, we're increasingly confident about the 6%-8% full-year growth guidance for TAVR. That's helpful. And then maybe one on the moderate AS. What is, I guess, a great way to think about moderate AS when these patients are untreated, right? Do they look like low-risk TAVR patients? Is this asymptomatic TAVR patients? What's the right way to think about moderate AS, and what's the underlying mortality rate in untreated moderate AS patients? Maybe let me start to the Vijay. First, when we decide to start a big pivotal study, randomized study, multi-year randomized studies like this one, it is because we believe we can show the benefit to patients. It is because we believe it is a big opportunity. It is because we believe in that case, SAPIEN 3 will have a big positive impact on these patients. So that's just to make sure that you feel our confidence and our belief behind PROGRESS and the moderate AS patient population. Having said that, we know the importance of highly scientific clinical studies. As a company relying a lot on world-class evidence, we are trying not to talk a lot about before having seen the results. We know the importance of it. So it is why some studies are more like post-market studies, marketing studies. So people have a freedom to talk about it. And here, we want to have a very high bar in terms of clinical evidence. So we have confidence, belief. It is a large patient population, and we are going to wait TCT to share more about it. Now, Dan, do you have anything that you want to share in addition to what I said here? Yeah, the only additional color that I would say is we learned a ton from our asymptomatic EARLY TAVR trial about how unpredictable the nature of the disease is. And this whole idea of that it's a progressive, predictable disease has been thrown out the window, even on EARLY TAVR. And this is not an asymptomatic trial, right? PROGRESS is not asymptomatic moderate, right? So we're talking about an asymptomatic patient population. And we don't know the results of the trial. We don't know what it looks like. What we do know is it enrolled very fast, right? And that's usually a bit of an indicator of things. And so we're excited to sort of just learn more about how this can inform this patient population and how transcatheter therapies may fit into this. But until we see the data, until we get past TCT, there's not a lot more to add. Thank you. And ladies and gentlemen, we have reached the end of the question-and-answer session. So I will now hand the floor back over to Bernard Zovighian for closing remarks. Thank you. Yeah, thank you so much. Thanks for your continued interest in Edwards. Scott, Gerianne, and myself welcome any additional questions by telephone. Thank you so much, and have a great rest of your day. Thank you. This concludes today's conference. All parties may disconnect. Thank you.